
3!
Infant Bacterial Therapeutics AB
(publ)
Annual Report 2022
IBT IN BRIEF
Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The
company’s Class B shares are since September 10, 2018, listed on Nasdaq Stockholm (IBT B).
Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a product in
clinical phase III with a vision to develop drugs influencing the infant microbiome, and thereby
prevent or treat rare diseases affecting infants.
IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to
become the world’s first approved probiotical drug with the goal to prevent life threatening
diseases in premature infants including Necrotizing Enterocolitis (NEC) and sepsis by conducting
sound stomach-and bowel development in premature infants. IBP-9414 contains the active
compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast
milk.
The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis,
a severe and rare disease affecting infants, IBP-1118 to prevent ROP (retinopathy of prematurity),
a growing and serious condition that often leads to blindness among prematurely born babies
and IBP-1122 for the prevention of antibiotic resistant hospital acquired infections. By
developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are
currently no prevention or treatment therapies available.
Vision
Premature infants are the most vulnerable beings on the planet and for them to survive, grow
and thrive they need intensive and specialized care. Although advances in medical care and
handling over the last 30 years have improved survival and well-being of these sensitive infants,
both in the immediate post-natal period and in their subsequent lives, current drugs and
therapies are mostly designed for adults and are not adapted to this specific and vulnerable
patient population. Specific treatment and prophylactic therapy are thus underdeveloped and
there is an urgent demand for drugs designed for the unique needs of the premature baby. IBT:s
vision is to become an internationally recognized and leading company in the development of
pharmaceuticals in the areas of premature babies, gastrointestinal diseases and probiotics.
Mission
IBT develops, and intends to market and sell, effective, safe and effective medicines that can
prevent or treat rare diseases. The company is focused around three areas of developed
competence:
● Gastroenterology - Enabling a healthy gut microbiome extends to multiple treatment
options, especially in combination with advanced gene modification possibilities.
● Premature babies - The need for premature treatment solutions is substantial, where IBT
has established a comprehensive global network of KOLs and institutions.